French finance minister criticises Sanofi’s $20 billion USA investment decision

PARIS (Reuters) -France’s finance minister criticised on Thursday a decision by French drugmaker Sanofi (NASDAQ:SNY) to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investing in the country rather than abroad.

"It’s clear it was not something that was nice to see and it was an unpleasant announcement," finance minister Eric Lombard told BFM Business TV.

"It sends out a bad signal," he also said, adding he hoped Sanofi would continue to invest in France.

The French drugmaker, one of the world’s largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday that it planned to expand its U.S. manufacturing capacity through direct investments in Sanofi sites, and partnerships with other domestic manufacturers.

Sanofi’s decision was the latest one from leading drugmakers which have been expanding their U.S. presence in response to President Donald Trump’s trade policies.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.SNY: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is SNY one of them?

Unlock ProPicks AI to find out